Loading provider…
Loading provider…
Urology Physician in Los Angeles, CA
NPI: 1134370422Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UCLA Urology Associates
uclahealth.org
HQ Phone
Get MD Brian's Phone Numberphone_androidMobile
Get MD Brian's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2006 - 2026
CT State Medical License
2013 - 2019
CA State Medical License

American Board of Urology
Urology
National Institutes of Health Clinical Center
Fellowship • Minimally Invasive Urologic Surgery
2010 - 2013
UCLA David Geffen School of Medicine/UCLA Medical Center
Residency • Urology
2005 - 2010
Internship • Transitional Year
2004 - 2005
New York University School of Medicine
Medical School
Until 2004
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 152 | 195 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 47 | 47 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 37 | 43 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 22 | 23 |
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Authors: Elizabeth Henske, Gordon Mills, Victor Reuter, Abraham Hakimi, Thai Ho, Sabina Signoretti, David Kwiatkowski, Wendy Rathmell, Toni Choueiri
Journal: Cell Rep
Publication Date: 2024-04-04
Authors: Cristianna Vallera, Allan Pantuck, Arie Belldegrun
Journal: J Urol
Publication Date: 2008-12-24
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
Authors: Christopher Corso, Ranjit Bindra
Publication Date: 2017-07-11
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: BeiGene, Driven To Cure
Intervention / Treatment: DRUG: Temozolomide, DRUG: Pamiparib
Lead Sponsor: Jonsson Comprehensive Cancer Center
Intervention / Treatment: OTHER: Questionnaire Administration, PROCEDURE: Single Photon Emission Computed Tomography, RADIATION: Technetium Tc-99m Sestamibi, PROCEDURE: Computed Tomography
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, OTHER: Quality-of-Life Assessment, PROCEDURE: Nephrectomy, OTHER: Patient Observation